{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T02:35:36Z","timestamp":1764729336046,"version":"3.46.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06698-z","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T01:56:21Z","timestamp":1762221381000},"page":"5905-5913","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Proinflammatory bone marrow niches and neutrophil activation are associated with TIGIT expression in multiple myeloma"],"prefix":"10.1007","volume":"104","author":[{"given":"Valeria","family":"Tomarchio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Arciprete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Di Cecca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Maricchiolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viola","family":"Velardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariantonietta","family":"Tafuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittoria","family":"Morano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Mecorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Rigacci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Crescenzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Zingariello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ombretta","family":"Annibali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"issue":"5","key":"6698_CR1","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV (2020) Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol 95(5):548\u2013567. https:\/\/doi.org\/10.1002\/ajh.25791","journal-title":"Am J Hematol"},{"issue":"5","key":"6698_CR2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M (2022) Diagnosis and management of multiple myeloma: a review. JAMA 327(5):464\u2013477. https:\/\/doi.org\/10.1001\/jama.2022.0003","journal-title":"JAMA"},{"issue":"4","key":"6698_CR3","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1172\/JCI66517","volume":"123","author":"AM Roccaro","year":"2013","unstructured":"Roccaro AM, Sacco A, Maiso P et al (2013) BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest 123(4):1542\u20131555. https:\/\/doi.org\/10.1172\/JCI66517","journal-title":"J Clin Invest"},{"issue":"2","key":"6698_CR4","first-page":"737","volume":"101","author":"SJ Choi","year":"2003","unstructured":"Choi SJ, Oba Y, Gazitt Y, Alsina M, Cruz J, Anderson J et al (2003) MIP-1\u03b1 is a potential osteoclast stimulatory factor in multiple myeloma. Blood 101(2):737\u2013744 PMID:14500557","journal-title":"Blood"},{"issue":"1","key":"6698_CR5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/nyas.13038","volume":"1364","author":"H Fairfield","year":"2016","unstructured":"Fairfield H, Falank C, Avery L, Reagan MR (2016) Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci 1364(1):32\u201351. https:\/\/doi.org\/10.1111\/nyas.13038","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"6698_CR6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41590-020-0665-3","volume":"1","author":"O Zavidij","year":"2020","unstructured":"Zavidij O, Haradhvala NJ, Mouhieddine TH et al (2020) Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer 1(5):493\u2013506. https:\/\/doi.org\/10.1038\/s41590-020-0665-3","journal-title":"Nat Cancer"},{"issue":"6","key":"6698_CR7","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMra052723","volume":"354","author":"IF Charo","year":"2006","unstructured":"Charo IF, Ransohoff RM (2006) The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354(6):610\u2013621. https:\/\/doi.org\/10.1056\/NEJMra052723","journal-title":"N Engl J Med"},{"issue":"9","key":"6698_CR8","first-page":"711","volume":"41","author":"C Silvestre-Roig","year":"2020","unstructured":"Silvestre-Roig C, Hidalgo A, Soehnlein O (2020) Neutrophil diversity in health and disease. Trends Immunol 41(9):711\u2013724 PMID:32153889","journal-title":"Trends Immunol"},{"key":"6698_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01933-x","volume":"9","author":"H Wang","year":"2024","unstructured":"Wang H, Kim SJ, Lei Y et al (2024) Neutrophil extracellular traps in homeostasis and disease. Sig Transduct Target Ther 9:235. https:\/\/doi.org\/10.1038\/s41392-024-01933-x","journal-title":"Sig Transduct Target Ther"},{"issue":"2","key":"6698_CR10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/nri.2017.105","volume":"18","author":"V Papayannopoulos","year":"2018","unstructured":"Papayannopoulos V (2018) Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol 18(2):134\u2013147 PMID:31170273","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"6698_CR11","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1038\/s41598-024-60642-3","volume":"14","author":"Z Zhao","year":"2024","unstructured":"Zhao Z, Li H, Wang Y, Li X, Jin J, Yu Y et al (2024) A neutrophil extracellular trap-related prognostic signature for multiple myeloma. Sci Rep 14(1):1802. https:\/\/doi.org\/10.1038\/s41598-024-60642-3","journal-title":"Sci Rep"},{"issue":"8","key":"6698_CR12","doi-asserted-by":"publisher","first-page":"10372","DOI":"10.1002\/cam4.7246","volume":"13","author":"G Gao","year":"2024","unstructured":"Gao G, Zhang L, Jin W, Xu H, Wang Y, Chen J et al (2024) Risk score constructed with neutrophil extracellular traps in multiple myeloma: association with immune status and drug sensitivity. Cancer Med 13(8):10372\u201310385. https:\/\/doi.org\/10.1002\/cam4.7246","journal-title":"Cancer Med"},{"issue":"3","key":"6698_CR13","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1055\/s-0034-1370765","volume":"40","author":"DD Wagner","year":"2014","unstructured":"Wagner DD (2014) NETosis: a new factor in tumor progression and cancer-associated thrombosis. Semin Thromb Hemost 40(3):277\u2013283","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"6698_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000957","volume":"8","author":"HM Zarour","year":"2020","unstructured":"Zarour HM (2020) Tigit in cancer immunotherapy. J Immunother Cancer 8(2):e000957. https:\/\/doi.org\/10.1136\/jitc-2020-000957","journal-title":"J Immunother Cancer"},{"issue":"5","key":"6698_CR15","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1182\/blood.2019000941","volume":"136","author":"C Guillerey","year":"2020","unstructured":"Guillerey C, Ferrari de Andrade L, Vuckovic S et al (2020) Immunosurveillance and immunoediting of multiple myeloma: implications for immunotherapy. Blood 136(5):556\u2013566. https:\/\/doi.org\/10.1182\/blood.2019000941","journal-title":"Blood"},{"issue":"1","key":"6698_CR16","doi-asserted-by":"publisher","first-page":"e150927","DOI":"10.1172\/JCI150927","volume":"132","author":"C Guillerey","year":"2022","unstructured":"Guillerey C, Harjunp\u00e4\u00e4 H, Carrie N et al (2022) TIGIT immune checkpoint Blockade restores NK cell anti-myeloma activity in mice and patients. J Clin Invest 132(1):e150927. https:\/\/doi.org\/10.1172\/JCI150927","journal-title":"J Clin Invest"},{"issue":"5","key":"6698_CR17","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1172\/JCI80445","volume":"125","author":"JM Chauvin","year":"2015","unstructured":"Chauvin JM, Zarour HM (2015) TIGIT and PD-1 impair tumor antigen-specific CD8\u207a T cells in melanoma patients. J Clin Invest 125(5):2046\u20132058. https:\/\/doi.org\/10.1172\/JCI80445","journal-title":"J Clin Invest"},{"issue":"4","key":"6698_CR18","doi-asserted-by":"publisher","DOI":"10.1172\/JCI157907","volume":"133","author":"SA Minnie","year":"2023","unstructured":"Minnie SA, Waltner OG, Ensbey KS, Olver SD, Collinge AD, Sester DP et al (2023) TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice. J Clin Invest 133(4):e157907. https:\/\/doi.org\/10.1172\/JCI157907","journal-title":"J Clin Invest"},{"issue":"6","key":"6698_CR19","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1182\/blood.2023021017","volume":"143","author":"L Wang","year":"2024","unstructured":"Wang L, Zhou L, Zhang J et al (2024) TIGIT Blockade overcomes resistance mediated by PVR-expressing macrophages in multiple myeloma. Blood 143(6):620\u2013634. https:\/\/doi.org\/10.1182\/blood.2023021017","journal-title":"Blood"},{"issue":"12","key":"6698_CR20","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV (2014) International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538\u2013e548. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"issue":"3","key":"6698_CR21","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"P Moreau","year":"2021","unstructured":"Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, H\u00e1jek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San-Miguel J, Sonneveld P, Mey U (2021) Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol 32(3):309\u2013322","journal-title":"Ann Oncol"},{"issue":"24","key":"6698_CR22","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC et al (2016) Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the international myeloma working group. Blood 127(24):2955\u20132962. https:\/\/doi.org\/10.1182\/blood-2016-01-631200","journal-title":"Blood"},{"issue":"8","key":"6698_CR23","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"B Paiva","year":"2016","unstructured":"Paiva B, Anderson KC et al (2016) International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328\u2013e346","journal-title":"Lancet Oncol"},{"issue":"11","key":"6698_CR24","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/dc.25366","volume":"52","author":"AM Naciu","year":"2024","unstructured":"Naciu AM, Bonfiglio R, Palumbo V, Maricchiolo G, Morano V, Salducci M, Stigliano S, Palermo A, Di Matteo FM, Crescenzi A (2024) From sampling to cellblock: the fully automated journey of cytological specimens. Diagn Cytopathol 52(11):611\u2013616","journal-title":"Diagn Cytopathol"},{"issue":"7490","key":"6698_CR25","first-page":"262","volume":"507","author":"L Comps-Agrar","year":"2014","unstructured":"Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y et al (2014) The immunoreceptor TIGIT regulates antitumor and antiviral CD8\u207a T cell effector function. Nature 507(7490):262\u2013266","journal-title":"Nature"},{"issue":"2","key":"6698_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000957","volume":"8","author":"HM Zarour","year":"2020","unstructured":"Zarour HM (2020) Tigit in cancer immunotherapy. J Immunother Cancer 8(2):e000957","journal-title":"J Immunother Cancer"},{"key":"6698_CR27","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","volume":"9","author":"S Thangavadivel","year":"2016","unstructured":"Thangavadivel S, Biedermann R, Strobl B, Schmidt WM, Lichtenegger FS et al (2016) T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol Oncol 9:116","journal-title":"J Hematol Oncol"},{"issue":"9983","key":"6698_CR28","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","volume":"385","author":"S Knop","year":"2015","unstructured":"Knop S, Bornh\u00e4user M (2015) Multiple myeloma. Lancet 385(9983):2197\u20132208","journal-title":"Lancet"},{"key":"6698_CR29","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nrc.2016.52","volume":"16","author":"S Wellenstein","year":"2016","unstructured":"Wellenstein S, M., de Visser K (2016) Neutrophils in cancer: neutral no more. Nat Rev Cancer 16:431\u2013446","journal-title":"Nat Rev Cancer"},{"issue":"22","key":"6698_CR30","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1158\/1078-0432.CCR-13-3203","volume":"20","author":"O Carranza-Rua","year":"2014","unstructured":"Carranza-Rua O, Alfaro C, O\u00f1ate C, Mart\u00edn-Algarra S, Perez G, Landazuri SF, Gonzalez A, Gross S, Rodriguez I, Mu\u00f1oz-Calleja C, Rodr\u00edguez-Ruiz M, Sangro B, L\u00f3pez-Picazo JM, Rizzo M, Mazzolini G, Pascual JI, Andueza MP, Perez-Gracia JL, Melero I (2014) Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins. Clin Cancer Res 20(22):5697\u20135707","journal-title":"Clin Cancer Res"},{"issue":"5","key":"6698_CR31","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.immuni.2020.03.001","volume":"52","author":"S Garasa","year":"2020","unstructured":"Garasa S, Gato M, Alfaro C, Migueliz I, Cirella A, de Andrea C, Ochoa MC, Otano I, Etxeberria I, Andueza MP, Nieto CP, Resano L, Azpilikueta A, Allegretti M, de Pizzol M, Ponz-Sarvis\u00e9 M, Rouzaut A, Schalper K, Carleton M, Mellado M, Rodriguez-Ruiz ME, Berraondo P, Perez-Gracia JL, Melero I (2020) CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity. Immunity 52(5):856\u2013871e8","journal-title":"Immunity"},{"key":"6698_CR32","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1038\/ncomms5539","volume":"5","author":"C Tripodo","year":"2014","unstructured":"Tripodo C, Chiodoni C, Guarnotta C, Cappetti B, Casalini P et al (2014) Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloma cells and promote their activation. Nat Commun 5:4539","journal-title":"Nat Commun"},{"issue":"8","key":"6698_CR33","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Bratman SV, Feng W, Kim D et al (2015) The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 21(8):938\u2013945","journal-title":"Nat Med"},{"issue":"6","key":"6698_CR34","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1158\/2643-3230.BCD-22-0011","volume":"3","author":"C Fern\u00e1ndez de Larrea","year":"2022","unstructured":"Fern\u00e1ndez de Larrea C, Kyle RA, Durie BGM, Ludwig H, Usmani SZ, Blad\u00e9 J et al (2022) Immune profiling and progression risk in smoldering multiple myeloma: results from a prospective study. Blood Cancer Discov 3(6):516\u2013531","journal-title":"Blood Cancer Discov"},{"issue":"3","key":"6698_CR35","first-page":"54","volume":"14","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Xu B, Meng L, Zhou J, Zhang Y, Song Q et al (2024) Single-cell transcriptomic and proteomic landscape reveals immune dysregulation from precursor States to multiple myeloma. Blood Cancer J 14(3):54","journal-title":"Blood Cancer J"},{"issue":"9","key":"6698_CR36","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1038\/s41375-022-01641-x","volume":"36","author":"B Paiva","year":"2022","unstructured":"Paiva B, Puig N, Cedena MT et al (2022) Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under Lenalidomide. Leukemia 36(9):2115\u20132126. https:\/\/doi.org\/10.1038\/s41375-022-01641-x","journal-title":"Leukemia"},{"key":"6698_CR37","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","volume":"1","author":"NJ Haradhvala","year":"2020","unstructured":"Haradhvala NJ, Mouhieddine TH, Sklavenitis-Pistofidis R, Cai S, Reidy M et al (2020) Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer 1:493\u2013506","journal-title":"Nat Cancer"},{"issue":"3","key":"6698_CR38","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1470-2045(21)00012-7","volume":"22","author":"ML Johnson","year":"2021","unstructured":"Johnson ML, Hussein MA, Cobo M, Patel AJ, Secen NM et al (2021) Primary analysis of a randomized, double-blind, phase II study of anti\u2013TIGIT antibody tiragolumab plus Atezolizumab versus placebo plus Atezolizumab in patients with PD-L1\u2013selected NSCLC (CITYSCAPE). Lancet Oncol 22(3):383\u2013393","journal-title":"Lancet Oncol"},{"issue":"1","key":"6698_CR39","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.it.2016.10.002","volume":"38","author":"EY Chiang","year":"2017","unstructured":"Chiang EY, Grogan JL (2017) TIGIT: a key inhibitor of the cancer immunity cycle. Trends Immunol 38(1):20\u201328","journal-title":"Trends Immunol"},{"issue":"9","key":"6698_CR40","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1182\/blood.2019000078","volume":"134","author":"SZ Usmani","year":"2019","unstructured":"Usmani SZ, Schjesvold F, Oriol A, Karlin L, Cavo M, Rifkin RM et al (2019) Pembrolizumab plus Lenalidomide and low-dose dexamethasone for relapsed\/refractory multiple myeloma: KEYNOTE-183 and KEYNOTE-185. Blood 134(9):701\u2013710. https:\/\/doi.org\/10.1182\/blood.2019000078","journal-title":"Blood"},{"issue":"16","key":"6698_CR41","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1182\/blood-2018-01-825265","volume":"132","author":"C Guillerey","year":"2018","unstructured":"Guillerey C, Harjunp\u00e4\u00e4 H, Carri\u00e9 N, Kassem S, Teo T, Miles K et al (2018) Tigit immune checkpoint blockade restores CD8\u207a T-cell immunity against multiple myeloma. Blood 132(16):1689\u20131694. https:\/\/doi.org\/10.1182\/blood-2018-01-825265","journal-title":"Blood"},{"issue":"10","key":"6698_CR42","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s43018-024-00818-w","volume":"5","author":"S Richard","year":"2024","unstructured":"Richard S, Lesokhin AM, Paul B, Kaufman JL, Pianko M, Biran N et al (2024) Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the mycheckpoint randomized clinical trial. Nat Cancer 5(10):1459\u20131464. https:\/\/doi.org\/10.1038\/s43018-024-00818-w","journal-title":"Nat Cancer"},{"issue":"3","key":"6698_CR43","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/17474086.2025.2469720","volume":"18","author":"V Tomarchio","year":"2025","unstructured":"Tomarchio V, Crescenzi A, Tafuri M, Verri M, Di Cecca M, Rigacci L, Annibali O (2025) The past, the present and the future of immune checkpoints inhibitors in multiple myeloma. Expert Rev Hematol 18(3):201\u2013214. https:\/\/doi.org\/10.1080\/17474086.2025.2469720","journal-title":"Expert Rev Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06698-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06698-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06698-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T02:30:58Z","timestamp":1764729058000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06698-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":43,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["6698"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06698-z","relation":{},"ISSN":["1432-0584"],"issn-type":[{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"8 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}